Literature DB >> 32020753

Cytokine and chemokine regulation of venous thromboembolism.

Maria Y Najem1, Francis Couturaud1, Catherine A Lemarié1,2.   

Abstract

Morbidity and mortality from venous thromboembolism (VTE), which refers to deep vein thrombosis and pulmonary embolism, have a substantial effect on the global burden of disease. The field of venous thrombosis research has been dramatically changed over the past 10 years with the improvement of animal models that shed some light on the interaction between inflammation and thrombosis. Important recent advances provided evidence of the implication of the innate immune system in venous thrombosis. In this review, we highlighted the cytokines and chemokines that regulate mechanisms of thrombus formation and resolution. Cytokines are pleiotropic, redundant, and multifunctional endogenous mediators orchestrating the inflammatory responses leading to thrombus formation or resolution. The use of experimental models has revealed the pro-thrombotic activity of some cytokines including interferon-γ, interleukin (IL)-6, chemokine ligand 2, IL-17A, IL-9, IL-1β, and transforming growth factor-β. Other cytokines such as IL-10, tumor necrosis factor-α, and IL-8 appear to promote thrombus resolution in late phase of venous thromboembolism. The purpose of this review is to bring together the current knowledge regarding the cytokines and chemokines that have been involved in thrombosis formation and resolution. We postulate that an imbalance between pro-thrombotic and anti-thrombotic cytokines/chemokines may be involved in the pathophysiology of VTE. However, in-depth basic and clinical research in venous thrombosis is still require to fully understand the precise mechanism of action of these cytokines.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  chemokine; cytokine; inflammation; thrombosis; vein

Mesh:

Substances:

Year:  2020        PMID: 32020753     DOI: 10.1111/jth.14759

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  15 in total

1.  Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma.

Authors:  Hamza Hashmi; Abu-Sayeef Mirza; Alicia Darwin; Constantine Logothetis; Franco Garcia; Anuhya Kommalapati; Rahul S Mhaskar; Christina Bachmeier; Julio C Chavez; Bijal Shah; Javier Pinilla-Ibarz; Farhad Khimani; Aleksandr Lazaryan; Hien Liu; Marco L Davila; Frederick L Locke; Taiga Nishihori; Michael D Jain
Journal:  Blood Adv       Date:  2020-09-08

Review 2.  Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors.

Authors:  Malinda T West; Thomas Kartika; Ashley R Paquin; Erik Liederbauer; Tony J Zheng; Lucy Lane; Kyaw Thein; Joseph J Shatzel
Journal:  Curr Probl Cancer       Date:  2022-01-10       Impact factor: 3.187

3.  Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study.

Authors:  Masaru Yoshimura; Yuichiro Fujieda; Masanari Sugawara; Michihito Kono; Masaru Kato; Isao Yokota; Olga Amengual; Yoichi M Ito; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2022-04-06       Impact factor: 3.580

Review 4.  Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities.

Authors:  Hannah Stevens; Karlheinz Peter; Huyen Tran; James McFadyen
Journal:  J Clin Med       Date:  2020-05-22       Impact factor: 4.241

5.  Identification of crucial genes mediating abdominal aortic aneurysm pathogenesis based on gene expression profiling of perivascular adipose tissue by WGCNA.

Authors:  Siliang Chen; Dan Yang; Bao Liu; Yuexin Chen; We Ye; Mengyin Chen; Yuehong Zheng
Journal:  Ann Transl Med       Date:  2021-01

Review 6.  Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?

Authors:  Przemysław J Kotyla; Małgorzata Engelmann; Joanna Giemza-Stokłosa; Bartosz Wnuk; Md Asiful Islam
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

Review 7.  Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.

Authors:  Shunsuke Mori; Fumihiko Ogata; Ryusuke Tsunoda
Journal:  Clin Rheumatol       Date:  2021-09-23       Impact factor: 2.980

8.  Transcriptomic Profiling of Femoral Veins in Deep Vein Thrombosis in a Porcine Model.

Authors:  Leszek Gromadziński; Łukasz Paukszto; Agnieszka Skowrońska; Piotr Holak; Michał Smoliński; Elżbieta Łopieńska-Biernat; Ewa Lepiarczyk; Aleksandra Lipka; Jan Paweł Jastrzębski; Marta Majewska
Journal:  Cells       Date:  2021-06-22       Impact factor: 6.600

Review 9.  Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.

Authors:  Vikas Bhuria; Conny K Baldauf; Burkhart Schraven; Thomas Fischer
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

Review 10.  Is the COVID-19 thrombotic catastrophe complement-connected?

Authors:  Edward M Conway; Edward L G Pryzdial
Journal:  J Thromb Haemost       Date:  2020-09-18       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.